Non-viral gene therapy Position Anjarium as a partner for researchers seeking non-viral delivery solutions to accelerate genetic medicine development, highlighting their enzymatic, cell-free platform for customizable DNA constructs across AAV, mRNA, and Lentivirus applications.

Swiss biotech leadership Leverage the company’s Switzerland headquarters and venture-backed growth to target European biotech customers prioritizing compliant, high-quality gene therapy tooling and scalable DNA construct synthesis.

Recent executive hiring Use the additions of a new CTO and expanded board as credibility signals to prospective customers and collaborators, offering discussions around advanced platform capabilities, strategic collaborations, and long-term roadmap alignment.

Strategic funding Frame funding history as validation of the technology trajectory and risk mitigation for partners; propose pilot collaborations to showcase scale, stability, and integration of synthetic DNA constructs into client pipelines.

Target growth verticals Identify opportunities with small-to-mid size biotech and contract development organizations focusing on non-viral gene therapies, offering a streamlined path to customizable DNA constructs for research, development, and commercialization workflows.